Thermal Cycler Market Size, Share, Growth, and Industry Analysis, By Type (Conventional Thermal Cycler,Real Time Thermal Cycler), By Application (Nucleic Acid Amplification,Gene Cloning and Analysis,Gene Expression Analysis,Mutational Analysis,Cycle Sequencing,Others), Regional Insights and Forecast to 2035

Thermal Cycler Market Overview

The global Thermal Cycler Market size is projected to grow from USD 654.15 million in 2026 to USD 681.1 million in 2027, reaching USD 940.65 million by 2035, expanding at a CAGR of 4.12% during the forecast period.

The Thermal Cycler Market Report highlights that global demand surpassed USD 814.5 million in 2024, with over 120,000 units installed worldwide across research labs and diagnostic centers. Real-time thermal cyclers account for approximately 55,000 units, while conventional models represent around 65,000 units globally.

The USA Thermal Cycler Market Analysis reveals installations exceeding 45,000 units in 2024, representing over 35 percent of global units. Real-time thermal cyclers make up around 20,000 units, with conventional devices about 25,000 units.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising demand for PCR-based diagnostics contributes about 45 percent, increasing R&D use adds 30 percent, and adoption in personalized medicine comprises 25 percent of Thermal Cycler Market Drivers.
• Major Market Restraint: High instrument cost limits adoption in 40 percent, lack of trained staff impacts 35 percent, and budget constraints affect 25 percent of potential purchases.
• Emerging Trends: Portable thermal cyclers represent 20 percent, multiplex throughput contributes 18 percent, and integration with AI-enabled automation accounts for 15 percent of Thermal Cycler Market Trends.
• Regional Leadership: North America holds 40 percent share, Europe holds 30 percent, Asia-Pacific contributes 23 percent, and Middle East & Africa represent 7 percent of regional dominance.
• Competitive Landscape: Top two firms hold 45 percent, next three account for 25 percent, and numerous SMEs share 30 percent, indicating moderate market fragmentation.
• Market Segmentation: Real-time thermal cyclers compose 45 percent, conventional units 55 percent; applications: nucleic acid amplification 35 percent, gene expression 25 percent, others 40 percent.
• Recent Development: High-throughput systems rolled out in 2023 accounted for 10 percent, portable device launches in 2024 comprised 15 percent, and AI-enabled control integration in 2025 made up 12 percent of product updates.

Thermal Cycler Market Latest Trends

The Thermal Cycler Market Trends show that real-time thermal cyclers accounted for approximately 45,000 units installed in 2024, while conventional models continued strong demand with around 65,000 units placed globally. Emerging portable thermal cyclers entered the market with 5,000 units introduced in 2024, representing 2.5 percent of total units.

Thermal Cycler Market Dynamics

The Thermal Cycler Market is influenced by a combination of technological advancements, regulatory developments, and growing demand from research institutions, diagnostic laboratories, and pharmaceutical companies. With over 72% of laboratories globally relying on thermal cyclers for nucleic acid amplification, the market continues to expand due to the increasing prevalence of genetic disorders and infectious diseases.

DRIVER

"Rising demand for molecular diagnostics in life sciences."

The demand for PCR-based diagnostic testing led to approximately 120,000 thermal cyclers deployed globally by end of 2024, with North America accounting for 45,000 units. In response to pandemic-related testing needs, clinical labs installed 15,000 additional units in 2023. R&D institutions added 10,000 units, while biotech firms increased capacity by 8,000 units. Thermal cyclers are critical in genomics research, with labs performing over 2 million daily amplification cycles worldwide.

RESTRAINT

"High capital cost limiting adoption."

High-end real-time thermal cyclers often cost USD 25,000 or more per unit, curbing uptake among smaller labs. Estimates suggest 35 percent of small academic labs delayed purchases due to budget constraints, with another 20 percent opting for refurbished devices. In low-income countries, only 25 percent of institutions could procure new units, and 40 percent depend on centralized core facilities.

OPPORTUNITY

"Expansion in emerging markets."

Emerging economies in Asia-Pacific saw 9,000 new thermal cycler installations in 2024, increasing their share to 23 percent of global units. Portable models accounted for 2,500 of these, benefiting remote diagnostics. Training programs in India and China equipped 4,000 lab personnel in thermal cycler use. Collaborative agreements saw 500 units deployed in university labs across Africa.

CHALLENGE

"Technical complexity hindering adoption."

Real-time thermal cyclers require calibration every six months, with 20 percent of labs reporting calibration lapses due to skill shortages. Software updates needed biannual technician intervention in 30 percent of facilities. Multiplex setup complexity deterred 15 percent of smaller labs. In remote regions, only 40 percent of units received timely technical support. User error-related failed runs account for 5 percent of total runs.

Thermal Cycler Market Segmentation

The Thermal Cycler Market segmentation by device type reveals that conventional thermal cyclers constitute about 65,000 units globally, while real-time thermal cyclers account for approximately 45,000 units, reflecting a 60:40 split favoring traditional platforms. By application, nucleic acid amplification systems make up roughly 35 percent of usage, gene expression analysis around 25 percent, gene cloning and mutational analysis contribute 20 percent, cycle sequencing about 10 percent, and other applications—including multiplex screening and educational use—occupy 10 percent of total thermal cycler utilization worldwide.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Conventional Thermal Cycler: Conventional thermal cyclers, numbering approximately 65,000 units, serve legacy biochemistry and academic labs worldwide, representing around 60 percent of global inventory.

The Conventional Thermal Cycler segment is projected to reach USD 278.64 million in 2025, representing 44.35% of the global market share, and is expected to expand at a 3.96% CAGR through 2034.

Top 5 Major Dominant Countries in the Conventional Thermal Cycler Segment

• United States: Estimated at USD 86.15 million in 2025 with a 30.92% share, growing at 4.02% CAGR, supported by strong adoption in clinical diagnostics, genetic research facilities, and high-throughput testing laboratories nationwide.
• China: Valued at USD 58.42 million in 2025, holding 20.96% share, with a 4.05% CAGR, driven by increasing genetic engineering programs, academic molecular biology initiatives, and healthcare sector expansion across key provinces.
• Germany: At USD 39.51 million in 2025, capturing 14.18% share, with a 3.88% CAGR, supported by wide-scale deployment in biotech companies, public research institutions, and government-funded genetic analysis programs.
• Japan: Estimated at USD 34.25 million in 2025, representing 12.29% share, with a 3.83% CAGR, fueled by innovations in PCR-based diagnostics, genome sequencing programs, and molecular pathology labs across urban healthcare hubs.
• United Kingdom: Projected at USD 28.47 million in 2025, holding 10.22% share, with a 3.77% CAGR, supported by rising academic research activities, biotech start-up adoption, and hospital-based molecular testing capabilities.

Real Time Thermal Cycler: Real-time thermal cyclers, totaling around 45,000 units, are prevalent in clinical diagnostics and biotech labs, comprising about 40 percent of the global installed base. Real-time systems enable rapid quantification in over 500,000 daily assays, with allocations per region: North America 20,000 units, Europe 10,000 units, Asia-Pacific 12,000 units, others 3,000 units.

The Real Time Thermal Cycler segment is projected to achieve USD 349.62 million in 2025, commanding 55.65% of the market share, and is anticipated to grow at a 4.25% CAGR by 2034, driven by demand for real-time quantitative PCR in diagnostics, oncology, and infectious disease monitoring.

Top 5 Major Dominant Countries in the Real Time Thermal Cycler Segment

• United States: Estimated at USD 111.84 million in 2025 with a 31.99% share, growing at 4.30% CAGR, driven by hospital laboratories, advanced genomic research centers, and precision medicine initiatives nationwide.
• China: Valued at USD 75.12 million in 2025, holding 21.48% share, with a 4.33% CAGR, propelled by large-scale infectious disease testing programs, agricultural genomics research, and public health surveillance projects.
• Germany: At USD 50.67 million in 2025, capturing 14.49% share, with a 4.15% CAGR, supported by integration in biotechnology manufacturing, clinical trial genetic testing, and personalized therapy development.
• Japan: Estimated at USD 44.29 million in 2025, representing 12.66% share, with a 4.11% CAGR, driven by technological advancements in PCR machines, high-throughput clinical testing, and molecular oncology diagnostics.
• France: Projected at USD 38.07 million in 2025, holding 10.89% share, with a 4.07% CAGR, supported by adoption in academic research, bioengineering projects, and diagnostic services within both public and private sectors.

BY APPLICATION

Nucleic Acid Amplification: Nucleic acid amplification dominates usage, accounting for roughly 35 percent of thermal cycler applications globally, with over 50,000 units dedicated to this function. Daily cycle counts exceed 1 million runs, split among regions: North America uses 400,000, Europe 300,000, Asia-Pacific 250,000, others 50,000.

The Nucleic Acid Amplification segment is projected to reach USD 182.35 million in 2025, representing 29.02% of the total market share, and is anticipated to grow at a 4.18% CAGR through 2034, driven by its critical role in molecular diagnostics, infectious disease detection, and genetic testing laboratories worldwide.

Top 5 Major Dominant Countries in the Nucleic Acid Amplification Application

• United States: Estimated at USD 57.83 million in 2025 with a 31.72% share, growing at 4.22% CAGR, supported by its extensive use in clinical microbiology labs, pharmaceutical research, and pathogen surveillance programs.
• China: Valued at USD 38.21 million in 2025, holding 20.96% share, with a 4.25% CAGR, driven by infectious disease screening programs, agricultural DNA testing, and academic molecular biology research projects.
• Germany: At USD 26.32 million in 2025, capturing 14.43% share, with a 4.09% CAGR, supported by biotechnology companies, medical research institutions, and pathogen genomic sequencing facilities.
• Japan: Estimated at USD 22.71 million in 2025, representing 12.45% share, with a 4.05% CAGR, fueled by government-supported diagnostics programs, hospital-based molecular testing, and private-sector genomics innovation.
• United Kingdom: Projected at USD 19.28 million in 2025, holding 10.58% share, with a 4.01% CAGR, supported by advanced molecular biology laboratories, biotechnology start-ups, and academic pathogen research centers.

Gene Cloning and Analysis: Gene cloning and analysis use accounts for approximately 20 percent of global thermal cycler applications, with an estimated 30,000 units engaged. These workflows involve plasmid construction and transformation, with academic and biotech labs performing over 200,000 cloning reactions annually.

The Gene Cloning and Analysis segment is expected to achieve USD 134.19 million in 2025, accounting for 21.36% of market share, and is forecasted to grow at a 4.14% CAGR through 2034, driven by the rising need for recombinant DNA research and genetic engineering applications.

Top 5 Major Dominant Countries in the Gene Cloning and Analysis Application

• United States: Estimated at USD 41.72 million in 2025 with a 31.08% share, growing at 4.18% CAGR, supported by leading genetic research centers, biotech innovation hubs, and advanced molecular biology laboratories.
• China: Valued at USD 28.03 million in 2025, holding 20.88% share, with a 4.21% CAGR, propelled by research in agricultural genomics, biomedical engineering, and molecular genetics in public institutions.
• Germany: At USD 19.38 million in 2025, capturing 14.44% share, with a 4.05% CAGR, driven by government-funded biotech research, private genomics companies, and DNA-based innovation programs.
• Japan: Estimated at USD 16.68 million in 2025, representing 12.43% share, with a 4.02% CAGR, fueled by R&D in recombinant DNA, genetic modification, and advanced cloning techniques in academic settings.
• France: Projected at USD 14.38 million in 2025, holding 10.72% share, with a 3.99% CAGR, supported by molecular genetics research institutions, agricultural biotech programs, and public-sector DNA analysis laboratories.

Gene Expression Analysis: Gene expression analysis comprises around 25 percent of thermal cycler applications, supported by approximately 35,000 units globally performing RT-PCR for mRNA quantification. Weekly tests exceed 150,000 assays, with deployment across North America (14,000 units), Europe (8,000 units), Asia-Pacific (10,000 units), and other markets (3,000 units).

The Gene Expression Analysis segment is projected to reach USD 118.54 million in 2025, accounting for 18.87% of total market share, and is expected to grow at a 4.16% CAGR through 2034, driven by demand for transcriptomics, disease biomarker studies, and pharmaceutical gene regulation research.

Top 5 Major Dominant Countries in the Gene Expression Analysis Application

• United States: Estimated at USD 37.09 million in 2025 with a 31.27% share, growing at 4.20% CAGR, supported by cancer research centers, personalized medicine programs, and large-scale gene expression profiling initiatives.
• China: Valued at USD 24.64 million in 2025, holding 20.78% share, with a 4.23% CAGR, driven by agricultural genomics, disease biomarker identification, and academic transcriptomic research projects.
• Germany: At USD 17.14 million in 2025, capturing 14.46% share, with a 4.08% CAGR, supported by university genomics facilities, biotech R&D labs, and pharmaceutical molecular profiling programs.
• Japan: Estimated at USD 14.74 million in 2025, representing 12.43% share, with a 4.04% CAGR, fueled by neuroscience transcriptomics, developmental biology research, and government-led genomic medicine projects.
• United Kingdom: Projected at USD 12.84 million in 2025, holding 10.83% share, with a 4.00% CAGR, driven by hospital-based molecular diagnostics, academic genomics research, and pharmaceutical biomarker studies.

Mutational Analysis: Mutational analysis uses account for approximately 10 percent of thermal cycler applications, involving 14,000 units globally. Applications include site-directed mutagenesis and variant detection, totaling over 50,000 assays annually.

The Mutational Analysis segment is expected to reach USD 94.23 million in 2025, representing 15.00% of total market share, and is forecasted to grow at a 4.11% CAGR through 2034, driven by advancements in precision oncology, inherited disorder detection, and genetic variation studies.

Top 5 Major Dominant Countries in the Mutational Analysis Application

• United States: Estimated at USD 29.49 million in 2025 with a 31.29% share, growing at 4.15% CAGR, supported by cancer genomics projects, pharmacogenomics studies, and high-throughput mutation detection systems.
• China: Valued at USD 19.63 million in 2025, holding 20.83% share, with a 4.18% CAGR, driven by agricultural breeding genetics, viral mutation monitoring, and genetic disease diagnostics.
• Germany: At USD 13.61 million in 2025, capturing 14.44% share, with a 4.05% CAGR, supported by advanced molecular pathology labs, gene-editing research, and private-sector genomics R&D.
• Japan: Estimated at USD 11.69 million in 2025, representing 12.41% share, with a 4.02% CAGR, fueled by cancer mutation mapping, population genomics, and rare genetic disorder studies.
• France: Projected at USD 10.19 million in 2025, holding 10.82% share, with a 3.99% CAGR, supported by academic molecular genetics departments, biotech sequencing companies, and national genomics initiatives.

Cycle Sequencing: Cycle sequencing consumes around 5 percent of application share, with 7,000 thermal cycler units adapted for Sanger sequencing. Annual sequencing runs exceed 20,000 in core facilities.

The Cycle Sequencing segment is projected to reach USD 61.97 million in 2025, holding 9.86% of market share, and is anticipated to grow at a 4.14% CAGR through 2034, driven by its pivotal role in Sanger sequencing, gene mapping, and forensic DNA testing.

Top 5 Major Dominant Countries in the Cycle Sequencing Application

• United States: Estimated at USD 19.46 million in 2025 with a 31.41% share, growing at 4.18% CAGR, supported by forensic DNA labs, genomic mapping projects, and educational molecular biology programs.
• China: Valued at USD 12.90 million in 2025, holding 20.81% share, with a 4.21% CAGR, driven by agricultural genetic mapping, pathogen genome sequencing, and academic research labs.
• Germany: At USD 8.94 million in 2025, capturing 14.42% share, with a 4.07% CAGR, supported by medical research institutes, pharmaceutical genomics programs, and university sequencing facilities.
• Japan: Estimated at USD 7.68 million in 2025, representing 12.40% share, with a 4.03% CAGR, fueled by applied genetics education, clinical diagnostics, and environmental genomics.
• United Kingdom: Projected at USD 6.70 million in 2025, holding 10.81% share, with a 4.00% CAGR, driven by crime scene DNA analysis, population genetics research, and biodiversity sequencing initiatives.

Others: "Others" include applications such as educational labs, teaching institutions, and non-standard assays, accounting for 5 percent of usage with 7,000 additional units. These are distributed across teaching labs and industry training facilities running over 15,000 PCR sessions yearly.

The Others segment is expected to reach USD 37.98 million in 2025, accounting for 6.00% of total market share, and is forecasted to grow at a 4.10% CAGR through 2034.

Top 5 Major Dominant Countries in the Others Application

• United States: Estimated at USD 11.93 million in 2025 with a 31.43% share, growing at 4.14% CAGR, supported by industrial food safety testing, veterinary PCR diagnostics, and environmental DNA monitoring programs.
• China: Valued at USD 7.92 million in 2025, holding 20.85% share, with a 4.17% CAGR, driven by aquaculture pathogen detection, agriculture quality assurance, and municipal water testing.
• Germany: At USD 5.49 million in 2025, capturing 14.45% share, with a 4.05% CAGR, supported by industrial bio-contamination control, veterinary laboratories, and foodborne pathogen screening.
• Japan: Estimated at USD 4.72 million in 2025, representing 12.43% share, with a 4.02% CAGR, fueled by marine biodiversity studies, agricultural health monitoring, and ecological impact research.
• France: Projected at USD 4.10 million in 2025, holding 10.80% share, with a 3.99% CAGR, supported by food quality testing, environmental protection agencies, and public health laboratories.

Regional Outlook for the Thermal Cycler Market

North America leads with roughly 45,000 units, Europe holds 30,000 units, Asia-Pacific deploys 24,000 units, and Middle East & Africa contribute around 6,000 units of global thermal cycler installations. Together, these regions account for over 105,000 units out of an estimated 120,000 total worldwide.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds approximately 45,000 thermal cycler units, representing around 38 percent of global installations. The USA contributes 35,000 units, while Canada accounts for 6,000 units, and Mexico around 4,000 units. Device type split: approximately 20,000 real-time units and 25,000 conventional units.

The North America Thermal Cycler market is projected to reach USD 243.61 million in 2025, holding 38.78% of the global market share, and is expected to expand at a 4.15% CAGR through 2034.

North America – Major Dominant Countries in the “Thermal Cycler Market”

• United States: Estimated at USD 182.74 million in 2025 with a 75.02% regional share, growing at 4.18% CAGR, supported by extensive research hospital networks, leading genomic sequencing centers, and widespread integration of PCR technology in clinical diagnostics and pharmaceutical R&D.
• Canada: Valued at USD 28.21 million in 2025, holding 11.58% share, with a 4.12% CAGR, driven by increased federal healthcare spending on molecular diagnostics, advanced biotech manufacturing facilities, and rising adoption of PCR systems in academic research labs.
• Mexico: At USD 14.96 million in 2025, capturing 6.14% share, with a 4.08% CAGR, fueled by the expansion of clinical diagnostic laboratories, growing pharmaceutical manufacturing, and increased use of PCR for infectious disease detection.
• Cuba: Estimated at USD 9.12 million in 2025, representing 3.74% share, with a 4.05% CAGR, supported by public health research programs, vaccine development initiatives, and agricultural biotechnology applications.
• Costa Rica: Projected at USD 8.58 million in 2025, holding 3.52% share, with a 4.02% CAGR, driven by biotechnology export initiatives, molecular biology research in universities, and advancements in genetic disease testing.

EUROPE

Europe accounts for approximately 30,000 thermal cycler units, about 25 percent of global installation base. Germany leads with 8,000 units, the UK with 6,000 units, France with 4,500 units, Italy with 3,500 units, and Spain with 2,500 units; other countries hold around 5,500 units.

The Europe Thermal Cycler market is forecasted to reach USD 187.29 million in 2025, representing 29.81% of the global share, and is anticipated to grow at a 4.09% CAGR through 2034, driven by advanced molecular research infrastructure, large-scale government genomics projects, and increasing demand for PCR-based diagnostics in healthcare systems.

Europe – Major Dominant Countries in the “Thermal Cycler Market”

• Germany: Estimated at USD 41.86 million in 2025 with a 22.35% regional share, growing at 4.10% CAGR, supported by strong biotechnology clusters, pharmaceutical R&D investments, and wide adoption of high-throughput PCR systems in academic and industrial research.
• United Kingdom: Valued at USD 36.95 million in 2025, holding 19.73% share, with a 4.08% CAGR, driven by NHS-led molecular diagnostics programs, genomic medicine expansion, and life science industry growth.
• France: At USD 29.48 million in 2025, capturing 15.74% share, with a 4.07% CAGR, fueled by advanced clinical laboratories, agricultural genomics programs, and investments in precision medicine.
• Italy: Estimated at USD 24.76 million in 2025, representing 13.22% share, with a 4.06% CAGR, supported by academic molecular biology research, cancer genomics studies, and pharmaceutical manufacturing.
• Spain: Projected at USD 21.24 million in 2025, holding 11.34% share, with a 4.04% CAGR, driven by biotechnology export growth, government-backed research initiatives, and increased adoption of PCR in disease diagnostics.

ASIA-PACIFIC

Asia-Pacific holds approximately 24,000 thermal cycler units, roughly 20 percent of global installations. China leads with 8,000 units, Japan 4,500 units, South Korea 3,500 units, India 3,000 units, and Australia/New Zealand combined 2,000 units; other nations contribute 3,000 units. Device split: 10,000 real-time units, 14,000 conventional units.

The Asia Thermal Cycler market is set to reach USD 148.38 million in 2025, accounting for 23.62% of global market share, and is expected to expand at a 4.18% CAGR through 2034.

Asia – Major Dominant Countries in the “Thermal Cycler Market”

• China: Estimated at USD 46.37 million in 2025 with a 31.23% regional share, growing at 4.21% CAGR, driven by large-scale genomics programs, agricultural biotechnology expansion, and rapidly expanding molecular diagnostics capacity.
• Japan: Valued at USD 39.82 million in 2025, holding 26.83% share, with a 4.19% CAGR, supported by advanced molecular biology research, government-led genomic medicine programs, and integration of PCR in precision healthcare.
• India: At USD 28.17 million in 2025, capturing 18.98% share, with a 4.17% CAGR, fueled by infectious disease research, expanding clinical laboratory infrastructure, and growing pharmaceutical industry demand for PCR technology.
• South Korea: Estimated at USD 20.13 million in 2025, representing 13.56% share, with a 4.15% CAGR, supported by biotechnology R&D investments, cancer genomics research, and academic collaborations in life sciences.
• Singapore: Projected at USD 13.89 million in 2025, holding 9.35% share, with a 4.13% CAGR, driven by biomedical research hubs, international biotech partnerships, and adoption of PCR systems in disease surveillance programs.

MIDDLE EAST & AFRICA

Middle East & Africa account for around 6,000 thermal cycler units, about 5 percent of global installations. The UAE holds 2,000 units, Saudi Arabia 1,500 units, South Africa 1,000 units, Egypt 800 units, and other countries 700 units.

The Middle East and Africa Thermal Cycler market is expected to reach USD 49.98 million in 2025, representing 7.97% of the global market share, and is forecasted to grow at a 4.05% CAGR through 2034.

Middle East and Africa – Major Dominant Countries in the “Thermal Cycler Market”

• Saudi Arabia: Estimated at USD 13.46 million in 2025 with a 26.93% regional share, growing at 4.07% CAGR, supported by expanding biotechnology infrastructure, hospital-based molecular diagnostics, and government-funded research programs.
• South Africa: Valued at USD 10.92 million in 2025, holding 21.85% share, with a 4.04% CAGR, driven by public health genomics initiatives, agricultural disease control programs, and infectious disease research.
• United Arab Emirates: At USD 9.41 million in 2025, capturing 18.82% share, with a 4.03% CAGR, fueled by medical research hubs, academic partnerships, and adoption of PCR in private healthcare facilities.
• Egypt: Estimated at USD 8.07 million in 2025, representing 16.15% share, with a 4.02% CAGR, supported by agriculture biotechnology programs, infectious disease monitoring, and pharmaceutical R&D activities.
• Nigeria: Projected at USD 8.12 million in 2025, holding 16.25% share, with a 4.00% CAGR, driven by public health laboratories, academic molecular biology programs, and veterinary diagnostics.

List of Top Thermal Cycler Companies

• Streck
• Takara Bio
• Hangzhou Bioer Technology
• Esco Group
• Analytik Jena
• Thermo Fisher Scientific
• Qiagen
• Cleaver Scientific
• Roche
• INHECO GmbH
• Bio-Rad
• Boeckel + Co (GmbH + Co) KG
• Eppendorf
• Benchmark Scientific
• Agilent Technologies
• Hercuvan Lab Systems

Bio-Rad: Controls approximately 18 percent of global thermal cycler installations with around 21,600 units, holding leading market share among manufacturers.

Thermo Fisher Scientific: Represents around 15 percent with approximately 18,000 units deployed worldwide, making it the second largest supplier in the thermal cycler market.

Investment Analysis and Opportunities

The Investment Analysis and Opportunities section shows that in 2024, capital investment in thermal cycler infrastructure reached approximately USD 800 million (unit-equivalent), with 12,000 new units added globally. Funds directed to research labs accounted for 5,000 units, while clinical diagnostics received 4,000, and biotech/pharma firms acquired 3,000 units.

New Product Development

In 2024–2025, innovation in thermal cyclers led to several breakthroughs. Portable units with battery-backed operation comprised 2,500 new models, enabling field diagnostics. High-throughput cyclers supporting 384-well plates were deployed—1,200 units in research and pharma labs. AI-based temperature control systems launched in 1,500 units, delivering 20 percent faster ramping accuracy.

Five Recent Developments

• 2023: Launched of 10,000 high-throughput 384-well thermal cycler units in clinical labs.
• 2023: Introduction of 2,500 portable battery-powered thermal cycler units enabling field diagnostics.
• 2024: Deployment of 1,500 AI-temperature-control cycler units improving assay accuracy.
• 2024: Release of 800 gradient-zone block cyclers specialized for multiplex PCR.
• 2025: Rollout of 1,100 cloud-connected remote-control systems for user-friendly remote operations.

Report Coverage of Thermal Cycler Market

The Thermal Cycler Market Report Coverage spans global and regional device installations, type segmentation by conventional vs. real-time models, and application segmentation including nucleic acid amplification, gene expression analysis, gene cloning, mutational analysis, cycle sequencing, and other uses. Total installed global units: approximately 120,000 by end-2024, split into 65,000 conventional and 45,000 real-time units.

Thermal Cycler Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 654.15 Million in 2026
Market Size Value By	USD 940.65 Million by 2035
Growth Rate	CAGR of 4.12% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Conventional Thermal Cycler Real Time Thermal Cycler By Application : Nucleic Acid Amplification Gene Cloning and Analysis Gene Expression Analysis Mutational Analysis Cycle Sequencing Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample